Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem ( 
Introduction
The COVID-19 pandemic originating in Wuhan, China is rapidly and continuously spreading globally and can result in serious significant respiratory morbidity and mortality. [1] . The responsible agent, SARS-CoV-2, is an enveloped RNA virus of the Coronaviridae virus family. Human-to-human transmission occurs through respiratory droplets or contaminated surfaces. [1] The average incubation period is 5 days, but ranges from [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] days. Most patients present with mild respiratory tract infection, mostly commonly characterized by fever (82%) and cough (81%). Severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in 14% of the reported cases, and the overall mortality is around 2%. 2 However, these numbers are in evolution as the pandemic spreads and depends on the country involved.
For COVID-19 patients who develop ARDS requiring intubation and mechanical ventilation, shock and multiple organ failure can also develop although whether this is a direct consequence of viral infection or complications of critical illness are not as yet clear.
Current therapeutic approaches include aggressive standard supportive care and treatment of any other co-infections. Anti-viral medications including remdesivir, lopinavir-ritonavir, or lopinavir-ritonavir and interferon beta-1 are under investigation but safety and potential efficacy remains to be determined. Remdesivir and interferon beta-1 appear to have superior antiviral activity to lopinavir and remdesivir in vitro for the MERS coronavirus but whether this is the case for SARS-CoV-2 remains to be determined. [2] The FDA has recently approved use of hydroxychloroquine in COVID-19 patients but the efficacy remains to be determined. Growing information also suggests that virus-induced cytokine storm in the lungs may drive severe pathogenesis and provide potential therapeutic targets, for example anti-IL6 or anti-IL-1 approaches. [3] More recently, a growing number of clinical investigations of cell-based therapies, primarily involving mesenchymal stem (stromal) cells (MSCs), but also utilizing MSCderived conditioned media (CM) or extracellular vesicles (EVs) and several other cell types, have been initiated in China for COVID-19 respiratory disease. As these encompass a wide range of approaches and targeted patient groups, it is imperative to better understand the rationale and the potential mechanisms of MSC actions towards respiratory viral infections. Recent pre-clinical data in models of respiratory virus infections and relevant related clinical studies of MSC administration in patients with ARDS can contribute to better define the patient population towards whom potential MSC-based cell therapy approaches might be considered.
Potential mechanisms of MSC actions in respiratory virus-induced lung injuries
Following systemic administration, the majority of MSCs lodge in the pulmonary vascular bed through as yet unclear interactions with the capillary endothelial cells. Tracking studies using labeled MSCs demonstrate the most are cleared within 24-48 hours although there can be longer persistence in injured or inflamed lungs. [4] The clearance mechanisms are still being elucidated but include apoptosis and subsequent effereocytosis and phagocytosis by resident inflammatory and immune cells, notably macrophages. [5] While lodged in the lungs, the MSCs are able to release a wide variety of soluble mediators including anti-inflammatory cytokines, [6] antimicrobial peptides, [7] angiogenic growth factors, and extracellular vesicles (EVs) (Figure 1 ). [8] Direct cell-cell transmission of mitochondria from MSCs to respiratory epithelial and immune cells [9] has also been described. [10] A growing literature demonstrates that the pattern of anti-inflammatory mediators released is specific for the inflammatory lung environment encountered and is mediated through differential activation of damage and pathogen-associated molecular pathogen receptors expressed on MSC cell surfaces. [11] [17] . Umbilical cord-derived MSCs (UC-MSCs) have also been shown to inhibit the cytotoxicity of specific T cells against H1N1 influenza virus in vitro, [18] leading perhaps to prolonged infection in recipients. This is in contrast to reports where, for example, in models of CMV infection, MSCs exert differential effects on alloantigen and virus specific T cells that retain the ability to proliferate, produce IFN-, and to kill CMV-infected cells in vitro. [19] An important question that remains to be resolved in respiratory virus infections is whether protective MSC actions are directly against viral infection, perhaps by stimulating anti-viral T cells actions, or whether they are due to overall anti-inflammatory actions have been demonstrated in other models of acute lung injuries. [20] The latter may be particularly relevant for cytokine storm and it is likely that a combination of actions will be responsible.
Effects of respiratory viruses on MSC actions
MSCs are generally resistant to viral infection compared to their differentiated progeny [21] .
In part this reflects intrinsic expression of interferon (IFN) stimulated genes (ISG) that preempt viral infection [21] . MSC ISG expression includes, among others, IFITM (interferon-induced transmembrane family), IFI6, ISG15, SAT1, PMAIP1, p21/CDKN1A and CCL2. Among these antiviral proteins, members of the IFITM family members are unique as they prevent infection before a virus can traverse the lipid bilayer of the cell.
These activities limit infection in cultured cells by many viruses, including dengue virus, Ebola virus, influenza A virus and SARS coronavirus. [22] Silencing of one of the most highly expressed ISGs in MSCs (p21/CDKN1A), specifically increased their susceptibility to chikungunya virus (CHIKV), whereas knockdown of IFITM3 rendered MSC susceptible to infection by a variety of viruses including YFV and ZIKV [21] .
Utilizing RNAseq (GSE97987) and validated by qRT-PCR, [21] we established a list of 
Do MSCs express ACE2, the functional receptor of SARS-CoV-2?
Angiotensin-converting enzyme 2 (ACE2) has been reported to be the main host cell receptor of the SARS-COv-2 entry and the serine protease TMPRSS2 for S protein priming. [28] ACE2 is highly expressed in respiratory epithelial cells thus playing a crucial role in the entry of virus into these cells. [29] ACE2 was recently also demonstrated to be an ISG in nasal epithelial cells. [30] Hence, SARS-CoV-2 may exploit IFN-driven upregulation of ACE2, a key tissue-protective mediator during lung injury, to enhance infection. Conversely, ACE2 was reported to protect against non-viral lung injury by degrading the profibrotic peptide angiotensin (Ang) II [31] . In vivo gene silencing of ACE2 enhances bleomycin-induced lung collagen deposition in mice, whereas systemic administration of purified ACE2 inhibits the fibrotic response [32] . Murine BM-MSCs over-expressing the ACE2 gene following lentiviral vector transduction, offered additional anti-inflammatory and endothelial-protective effects against endotoxin-induced lung injury in mice. [33] , [34] However, there may be a downside to this if ACE2 over-expression results in infection and subsequent deleterious effects on the MSCs. As the level of gene expression is a key determinant of SARS-CoV-2 transmissibility, [28] it is relevant to assess whether MSCs of any origin constitutively or inducibly express ACE2 or TMPRSS2.
MSCs in respiratory virus-related lung injury: Pre-clinical evidence
There is a large literature demonstrating efficacy of either systemic or direct intratracheal MSC administration in pre-clinical models of respiratory diseases including those involving acute lung injury induced by bacterial or bacterial products (endotoxin) or other means. [35] The models include both rodents as well as large animal ( injections. As best as we can ascertain, here is no apparent pre-clinical data to support the rationale for any of these approaches.
Ethical issues for considering cell-based approaches for respiratory virus infections
Activities of health care providers and researchers during an infectious disease outbreak, including clinical trials, are aimed towards finding rapid and effective responses for the treatments of infected patients. These actions need to occur under appropriate ethical guidelines. The WHO has guidelines which embed ethical approaches and considerations within the integrated global alert and response system for epidemics and other public health emergencies. [51] These are all applicable to cell-based clinical investigations and include assurance that these are scientifically valid and that potential risks are reasonable in relation to anticipated benefits. With respect to safety of MSC administration in critically ill patients including those with ARDS resulting from other etiologies, no significant issues have been described in published articles to date. [51] . With respect to efficacy, there is equipoise at present as only one as yet unpublished exploratory trial of MSC administration has demonstrated beneficial outcomes. [52] It is also imperative that the clinical investigations be conducted in a transparent manner according to established precedents for clinical investigations of potential new therapies for critical illnesses. [53] This includes recognized endpoints, including but not limited to overall mortality, length of ICU and hospital stay and ventilator-free days. We also strongly The available pre-clinical data and the safety data from clinical trials in non-viral ARDS best supports potential use. As it is too early to tell whether there will be any downstream respiratory effects in COVID-19 ARDS survivors, this seems a less urgent population to target. Similarly, targeting recovering mild or moderately affected patients to counter as yet unknown downstream effects on the lungs also seems to be a less urgent consideration.
Overall, to date there has been a limited understanding of the pathogenesis of COVID-19, which currently hinders the development of an optimal study design Whether to utilize genetically modified MSCs is unclear at present. This in part reflects the current lack of understanding as to which action, ie., secreted mediator constitutively or inducibly produced by MSCs, may be most effective in SARS-CoV-2 respiratory infections. This also reflects the lack of clear evidence at present as to whether any other potentially therapeutic agent, for example an IL-6 or IL-1 receptor antagonist that the MSCs could be engineered to produce, also will have proven efficacy. This may change rapidly as current treatment investigations involving these and other agents evolve.
Further, as genetically modified cell products require a more a more lengthy regulatory approval, this may not be a strategy of choice to face the current outbreak.
Challenges and Perspectives
The global pandemic of COVID19 repiratory infection has prompted urgent need for novel therapies. Clinical and basic science investigators need to take the lead by promoting and adhering to rigorously designed investigations logically based on available pre-clinical data. The limited available data regarding MSC administration in pre-clinical respiratory disease injury models and current understanding of potential mechanisms of MSC actions in lung injury models can be cautiously and carefully utilized to support rationally designed and conducted clinical investigations. However, more pre-clinical data is necessary, particularly in models of coronavirus-induced lung injuries. While compassionate use of unproven MSC-based therapies may be contemplated in different circumstances, we urge that whenever possible, this take place in the larger context of a clinical investigation. Since the original writing of this review, a number of academic and industry sponsored trials of MSC-based investigations have been initiated globally in addition to the ones in China reviewed. We urge all of these to uphold the highest standards for rationale and approrpaitely designed investigations. Only in these ways can a rationale evidence-based platform for potential therapeutic use of cell-based therapies be developed.
We must also take strong stance against the stem cell clinic industry which has already begun to offer unproven therapies for COVID19. The ISCT, ISSCR, and a number of other professional and scientific organizations have taken leadership positions in this area. [54] , [55] , [56] . The potential for abuse is high given the desperate circumstances of the COVID-19 pandemic and unauthorized use of unproven therapies is a clear danger.
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